These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19878649)

  • 1. PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion.
    Langhi C; Le May C; Gmyr V; Vandewalle B; Kerr-Conte J; Krempf M; Pattou F; Costet P; Cariou B
    Biochem Biophys Res Commun; 2009 Dec; 390(4):1288-93. PubMed ID: 19878649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
    Ferri N; Tibolla G; Pirillo A; Cipollone F; Mezzetti A; Pacia S; Corsini A; Catapano AL
    Atherosclerosis; 2012 Feb; 220(2):381-6. PubMed ID: 22176652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities.
    Mbikay M; Sirois F; Mayne J; Wang GS; Chen A; Dewpura T; Prat A; Seidah NG; Chretien M; Scott FW
    FEBS Lett; 2010 Feb; 584(4):701-6. PubMed ID: 20026049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substantial PCSK9 inactivation in β-cells does not modify glucose homeostasis or insulin secretion in mice.
    Peyot ML; Roubtsova A; Lussier R; Chamberland A; Essalmani R; Murthy Madiraju SR; Seidah NG; Prentki M; Prat A
    Biochim Biophys Acta Mol Cell Biol Lipids; 2021 Aug; 1866(8):158968. PubMed ID: 33992809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic PCSK9 controls the organization of the β-cell secretory pathway via LDLR-cholesterol axis.
    Marku A; Da Dalt L; Galli A; Dule N; Corsetto P; Rizzo AM; Moregola A; Uboldi P; Bonacina F; Marciani P; Castagna M; Catapano AL; Norata GD; Perego C
    Metabolism; 2022 Nov; 136():155291. PubMed ID: 35981632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
    Starr AE; Lemieux V; Noad J; Moore JI; Dewpura T; Raymond A; Chrétien M; Figeys D; Mayne J
    FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.
    Schmidt RJ; Beyer TP; Bensch WR; Qian YW; Lin A; Kowala M; Alborn WE; Konrad RJ; Cao G
    Biochem Biophys Res Commun; 2008 Jun; 370(4):634-40. PubMed ID: 18406350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variable effects of gender and Western diet on lipid and glucose homeostasis in aged PCSK9-deficient C57BL/6 mice CSK9PC57BL/6.
    Mbikay M; Sirois F; Gyamera-Acheampong C; Wang GS; Rippstein P; Chen A; Mayne J; Scott FW; Chrétien M
    J Diabetes; 2015 Jan; 7(1):74-84. PubMed ID: 24548670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mice Fed a High-Cholesterol Diet Supplemented with Quercetin-3-Glucoside Show Attenuated Hyperlipidemia and Hyperinsulinemia Associated with Differential Regulation of PCSK9 and LDLR in their Liver and Pancreas.
    Mbikay M; Mayne J; Sirois F; Fedoryak O; Raymond A; Noad J; Chrétien M
    Mol Nutr Food Res; 2018 May; 62(9):e1700729. PubMed ID: 29396908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue.
    Roubtsova A; Munkonda MN; Awan Z; Marcinkiewicz J; Chamberland A; Lazure C; Cianflone K; Seidah NG; Prat A
    Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):785-91. PubMed ID: 21273557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor.
    Da Dalt L; Ruscica M; Bonacina F; Balzarotti G; Dhyani A; Di Cairano E; Baragetti A; Arnaboldi L; De Metrio S; Pellegatta F; Grigore L; Botta M; Macchi C; Uboldi P; Perego C; Catapano AL; Norata GD
    Eur Heart J; 2019 Jan; 40(4):357-368. PubMed ID: 29982592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.
    Maxwell KN; Fisher EA; Breslow JL
    Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2069-74. PubMed ID: 15677715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.
    Maxwell KN; Breslow JL
    Proc Natl Acad Sci U S A; 2004 May; 101(18):7100-5. PubMed ID: 15118091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.
    Lambert G; Jarnoux AL; Pineau T; Pape O; Chetiveaux M; Laboisse C; Krempf M; Costet P
    Endocrinology; 2006 Oct; 147(10):4985-95. PubMed ID: 16794006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system.
    Poirier S; Prat A; Marcinkiewicz E; Paquin J; Chitramuthu BP; Baranowski D; Cadieux B; Bennett HP; Seidah NG
    J Neurochem; 2006 Aug; 98(3):838-50. PubMed ID: 16893422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice.
    Roubtsova A; Chamberland A; Marcinkiewicz J; Essalmani R; Fazel A; Bergeron JJ; Seidah NG; Prat A
    J Lipid Res; 2015 Nov; 56(11):2133-42. PubMed ID: 26323289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.